Minute Insight: Insulet Launches Omnipod 5 US-Wide Following Trial Period
After six months, the Omnipod 5 has seen its limited market launch expanded to cover the entirety of the US market.
You may also be interested in...
Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.
JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.
Insulet has recalled its Omnipod DASH personal diabetes manager after reports from users of battery issues. The company says it is replacing the devices.